Meralys Intensive nasal spray 10 ml — Made in Croatia — Free Deliver

Product description

Nasal spray "Meralys ® Intensive" is used for the symptomatic treatment of nasal congestion and rhinorrhea in respiratory diseases.

Structure

1 ml of the medicinal product contains (active ingredients):

• ipratropium bromide - 0.6 mg;
• xylometazoline hydrochloride - 0.5 mg.

Excipients: purified sea water, disodium edetate, glycerin 85%, hydrochloric acid and sodium hydroxide (for pH correction), purified water.

Contraindications

• hypersensitivity to any components of the preparation;
• hypersensitivity to atropine or similar agents, such as hyoscyamine, scopolamine;
• past surgical interventions on the dura mater of the brain, for example, transphenoidal hypophysectomy or other transnasal operations;
• acute coronary diseases, coronary asthma, hyperthyroidism;
• glaucoma;
• dry rhinitis;
• children's age (up to 18 years old).

Mode of application

Applied intranasally.

The recommended dose for adults is one injection 3 times a day in each nasal passage. The interval between the use of Meralys ® Intensive should be at least 6 hours.

Before the first use, it is necessary to do several sprays into the air (4 times) to achieve dose uniformity. The bottle must be kept upright. If the product is not used for several days (more than 6 days), it is necessary to make two sprays into the air in order to achieve a uniform dose.

After use, the spray device should be wiped thoroughly with a clean paper towel and the protective cap replaced.

To minimize the risk of spreading infection, the medicine should not be used by more than one person.

The duration of treatment should not exceed 7 days. Long-term treatment with xylometazoline hydrochloride can cause swelling of the nasal mucosa and increased secretion, which is due to increased sensitivity of cells - "the opposite effect".

After the disappearance of the symptoms of the disease, it is recommended to discontinue treatment with the preparation in order to avoid the risk of developing adverse reactions, even if the duration of treatment is less than 7 days.

The experience of using the preparation in elderly patients (over 70 years old) is limited.

One injection (approximately 140 μl) of Meralys ® Intensive contains approximately 70 μg of xylometazoline hydrochloride and 84 μg of ipratropium bromide.

Application features

Pregnant

There is not enough data on the use of the preparation during pregnancy. Preclinical data are insufficient to assess the effect of the preparation on pregnancy, embryo / fetal development, childbirth and postpartum development. The potential risk to humans is unknown. The preparation should not be used during pregnancy unless absolutely necessary.

There are no data on the penetration of ipratropium bromide and xylometazoline hydrochloride into breast milk. The systemic effect of ipratropium bromide and xylometazoline hydrochloride is low. Therefore, impact on a breastfed infant is unlikely. It is necessary to assess the need to use the preparation "Meralys ® Intensive" for a woman, the benefits of breastfeeding and the potential risk to the baby. Exceeding the recommended dose is unacceptable.

Children

The preparation is not used in children (under the age of 18) due to insufficient data.

Drivers

When using the preparation, visual disturbances (including blurred vision and dilated pupils), dizziness and fatigue may occur. Patients should be warned that if such reactions occur, it is necessary to avoid driving or operating machinery and not to participate in activities that may endanger health or life.

Overdose

With an oral overdose or with excessive local use of xylometazoline hydrochloride, the following phenomena are possible: severe dizziness, excessive sweating, a sharp drop in body temperature, headache, bradycardia, arterial hypertension, respiratory depression, coma and convulsions. After arterial hypertension, arterial hypotension may develop. Children are more susceptible to toxicity than adults. Treatment is symptomatic.

With excessive intranasal use of ipratropium bromide, an acute overdose is unlikely due to the very insignificant absorption of the preparation into the blood during oral and intranasal administration, but symptoms such as dry mouth, difficulty in accommodation, tachycardia may develop. Treatment is symptomatic.

A significant overdose can cause anticholinergic symptoms from the central nervous system, including hallucinations, for which cholinesterase inhibitors are prescribed.

Appropriate supportive measures are required for all individuals with suspected overdose; emergency symptomatic therapy under the supervision of a physician is prescribed if necessary. The patient should be observed for at least 6 hours. In case of severe overdose with cardiac arrest, resuscitation should be carried out for at least 1 hour.

Side effects

The most common side effects are epistaxis (14.8%) and dry nose (11.3%).

Storage conditions

Does not require special storage conditions. Keep out of the reach of children.

Shelf life is 3 years.